How to Tell If You’re Losing Muscle on a GLP-1: A Practical Monitoring Checklist

Losing weight on a GLP-1 medication does not automatically mean you are losing a harmful amount of muscle. The scale cannot distinguish body fat from water, lean tissue, or skeletal muscle, and even a body-composition scan does not tell the whole story about muscle health.

A more useful approach is to monitor several things together: strength, everyday physical function, exercise performance, food intake, rate of weight loss, and—when appropriate—body composition. Current GLP-1 guidance increasingly emphasizes this broader view because muscle health involves more than simply how many pounds of lean mass appear on a scan.

This checklist is designed to help identify changes worth paying attention to. It cannot diagnose muscle loss or sarcopenia, but it can help you recognize patterns that may deserve a closer look.

First, know what you are actually trying to monitor

The phrase “muscle loss” can mean several different things.

Clinical studies of GLP-1 medications often measure lean mass or fat-free mass, which includes more than skeletal muscle. Depending on the testing method, these measurements can also reflect organs, connective tissue, glycogen-associated water, and other non-fat components.

A 2026 systematic review cautioned that reductions in measured lean mass during GLP-1 therapy should not automatically be interpreted as sarcopenia or clinically important skeletal-muscle loss. At the same time, the authors noted that current evidence is not strong enough to rule out meaningful muscle loss in susceptible individuals.

Muscle health itself has several dimensions:

• Muscle quantity: how much muscle tissue you have.
• Muscle strength: how much force you can produce.
• Muscle quality: how effectively the muscle functions relative to its size and composition.
• Physical performance: how well muscle supports activities such as walking, climbing stairs, rising from a chair, and carrying objects.

This distinction is consistent with established sarcopenia guidance. The European Working Group on Sarcopenia in Older People considers low muscle strength a key characteristic, with low muscle quantity or quality used to confirm the diagnosis and poor physical performance indicating greater severity.

For someone taking a GLP-1 medication, this means the goal is not merely to watch one body-composition number. It is to look for meaningful trends across several areas.

The GLP-1 muscle-monitoring checklist:

1. Is your strength staying reasonably stable?

One of the most practical things to track is whether you are becoming noticeably weaker over time.

If you strength train, your workout log can provide useful information. You might track:

• the amount of resistance used;
• the number of repetitions completed;
• the number of sets performed;
• whether familiar exercises are becoming easier, stable, or progressively harder;
• whether technique is deteriorating despite normal effort.

A single poor workout does not mean you have lost muscle. Sleep, stress, illness, hydration, calorie intake, and accumulated training fatigue can all temporarily lower performance.

What matters more is a persistent downward trend.

For example, suppose you have regularly performed a leg press with a certain resistance for 10 controlled repetitions. If that drops to nine repetitions one week and returns to normal the next, there may be little reason for concern.

If performance falls steadily for several weeks across multiple exercises while body weight is also dropping rapidly, that pattern deserves more attention.

Strength is particularly valuable because muscle quantity and muscle function do not always change together. A prospective 2026 semaglutide study, for example, reported an initial decline in lean mass followed by stabilization, while handgrip strength improved over 12 months. That study was observational rather than a randomized comparison, but it illustrates why declining lean mass does not automatically equal declining function.

Checklist question:
Are you maintaining, improving, or at least not steadily losing strength in movements you perform regularly?

2. Are everyday tasks becoming harder?

You do not have to belong to a gym to notice changes in muscle function.

Daily activities can provide valuable clues about whether strength and mobility are holding up.

Pay attention to tasks such as:

• rising from a chair without using your arms;
• climbing a familiar flight of stairs;
• carrying grocery bags;
• getting up from the floor;
• lifting household objects;
• walking at your usual pace;
• performing yardwork or other routine physical tasks.

The 2025 multisociety GLP-1 advisory notes that measures such as sit-to-stand performance, stair climbing, and timed mobility tests can be useful for monitoring function, particularly in older adults.

These tasks are not diagnostic tests when performed casually at home. A bad knee, back pain, arthritis, shortness of breath, or another condition could also make them more difficult.

The important question is whether something that used to feel routine is becoming progressively more difficult without an obvious alternative explanation.

Checklist question:
Can you still perform your usual daily activities with roughly the same strength and confidence?

3. Is your resistance-training performance progressing—or steadily declining?

Strength training serves two purposes here.

First, it helps preserve muscle during weight loss. Second, it gives you a repeatable way to observe what your muscles are capable of doing.

Someone who regularly performs the same core exercises can compare performance over time much more easily than someone whose exercise routine changes completely every few days.

Useful trends might include:

• maintaining the same resistance as body weight falls;
• gradually adding repetitions;
• gradually increasing resistance;
• improving exercise technique or range of motion.

Maintaining strength while losing a substantial amount of body weight can itself be meaningful progress.

By contrast, repeatedly needing to lower resistance across several major muscle groups may warrant closer attention, especially if the change coincides with very low food intake, inactivity, illness, or rapid weight loss.

Do not interpret every plateau as muscle loss. Strength improvements are rarely perfectly linear, especially during a calorie deficit.

Checklist question:
Across the past month or two, is your overall training performance reasonably stable rather than consistently moving backward?

4. Are you eating enough protein—and enough food overall?

Monitoring muscle health without monitoring nutrition leaves out an important part of the picture.

GLP-1 medications can substantially reduce appetite. Some people also experience nausea, early fullness, food aversions, vomiting, or other gastrointestinal effects that make eating difficult.

Current consensus guidance recommends paying attention not only to protein intake but also to overall dietary quality, micronutrient risk, and nutritional adequacy during incretin-based therapy.

Warning patterns can include:

• routinely skipping meals because you have no appetite;
• regularly reaching late afternoon having eaten very little;
• eating very small portions with little protein;
• avoiding many foods because of nausea;
• relying almost entirely on snack foods or liquids with limited nutritional value;
• persistent difficulty drinking enough fluids.

Protein deserves particular attention because it supplies amino acids used in muscle maintenance and repair, but simply adding a protein shake does not fix a chronically inadequate diet.

A short food record can sometimes reveal gaps that are easy to miss. If appetite is low, you may discover that meals you perceive as “normal” are now much smaller than they were before treatment.

Checklist question:
Are you regularly getting adequate protein and a varied diet, or has appetite suppression made your total intake unusually low?

5. How quickly is your body weight changing?

There is no single rate of weight loss that proves muscle is being lost.

Weight-loss trajectories vary substantially according to starting weight, medication, dosage, nutrition, physical activity, medical conditions, and individual response.

Still, rapid weight loss combined with poor nutrition, inactivity, and declining strength creates a different picture from weight loss accompanied by adequate nutrition, resistance training, and stable function.

The 2025 multisociety advisory recommends monitoring muscle and nutritional status particularly when weight-loss trajectories are substantial or when other risk factors are present.

Rather than focusing on one week’s scale result, look at the longer trend.

Ask:

• Has weight loss suddenly accelerated?
• Has that change occurred at the same time as severe appetite suppression?
• Are you also eating much less protein?
• Has your exercise performance deteriorated?
• Are you feeling progressively weaker?

The combination of several changes is generally more informative than any one number.

Checklist question:
Is your weight-loss trend occurring alongside stable nutrition and function, or are rapid losses appearing together with weakness and poor intake?

6. Are you becoming less physically active without realizing it?

Formal workouts are only one part of movement.

When food intake declines substantially, some people may feel more tired and unconsciously reduce their normal daily activity. Walking may decline. Household tasks may become less frequent. More time may be spent sitting.

That reduction matters because muscle responds to how much it is used.

Someone can technically complete two strength workouts per week while still becoming much more sedentary during the other five days.

Current GLP-1 guidance recommends combining resistance training with broader physical activity rather than treating exercise as an isolated event.

A fitness tracker is not required. You can simply compare your current routine with what was normal before treatment.

For example:

• Are you still taking your usual walks?
• Are you avoiding stairs you previously used?
• Do you feel too tired to complete normal household activities?
• Are you sitting substantially more because of fatigue?

A temporary decline during illness or medication adjustment may be understandable. A persistent decline deserves more consideration.

Checklist question:
Has your ordinary daily movement remained stable, or has reduced energy quietly made you much less active?

7. What does body-composition testing show?

Body-composition measurements can add useful information when interpreted carefully.

DXA

Dual-energy X-ray absorptiometry, or DXA, can estimate fat mass, lean soft tissue, and bone mineral content. It is commonly used in research examining body-composition changes during GLP-1 treatment.

DXA can help show whether a substantial change in body weight is predominantly fat or lean tissue.

However, DXA lean mass is not a direct measurement of skeletal muscle. Changes in hydration and other components of lean tissue can influence the result.

BIA

Bioelectrical impedance analysis, or BIA, estimates body composition partly through the body’s electrical conductivity.

Its advantages include convenience, relatively low cost, and the ability to repeat measurements over time. The multisociety GLP-1 advisory identifies BIA as a pragmatic option for repeated monitoring in some clinical settings.

But BIA can be affected by hydration status, food intake, exercise, and other factors. Consumer smart scales may also vary considerably in precision.

If BIA is used to monitor trends, measurements are generally more useful when conditions are reasonably consistent from one test to the next.

CT and MRI

Computed tomography and MRI can provide more direct information about muscle size and distribution and can sometimes evaluate features related to muscle quality.

They are primarily research or clinically indicated tools rather than routine muscle-monitoring tests for every person taking a GLP-1 medication.

A 2026 review of GLP-1 muscle preservation emphasizes that DXA, BIA, imaging, strength testing, and functional assessment answer somewhat different questions. No single method captures muscle quantity, quality, and function simultaneously.

Checklist question:
If you are using body-composition testing, are you looking at the trend alongside strength and function rather than treating one scan as a diagnosis?

8. Are several warning signs appearing together?

The most useful monitoring strategy looks for patterns.

One change by itself may have a harmless explanation.

For example, you might have a weak workout after sleeping poorly. Your BIA scale might report lower lean mass after a dehydrating illness. Stair climbing might temporarily be harder because of knee pain.

Concern rises when several changes occur at the same time.

A pattern worth discussing with your healthcare team might look like:

• substantial ongoing weight loss;
• very low food or protein intake;
• persistent nausea or vomiting;
• declining resistance-training performance;
• increasing difficulty with routine physical tasks;
• prolonged inactivity;
• repeated body-composition measurements suggesting substantial lean-tissue loss.

This does not prove that GLP-1 medication is causing pathological muscle loss.

It does indicate that a broader clinical assessment may be worthwhile.

A simple monthly muscle-health check

For someone without major baseline muscle-health concerns, there is usually no need to perform elaborate testing every day.

A simple periodic review can be more useful:

What to monitor	Question to ask
Body weight	What is the overall trend rather than today’s number?
Strength training	Am I maintaining or progressing on familiar exercises?
Daily function	Are stairs, chairs, carrying, and walking becoming harder?
Protein intake	Am I regularly including meaningful protein sources?
Overall food intake	Has appetite suppression caused prolonged under-eating?
Activity	Am I moving about as much as usual outside workouts?
Medication effects	Are nausea or other symptoms interfering with eating or activity?
Body composition	If measured, is the trend being interpreted with strength and function?

The objective is not to create anxiety about normal fluctuations. It is to establish enough awareness that a meaningful downward trend does not go unnoticed.

What about grip-strength tests?

Handgrip dynamometry is commonly used in research and clinical assessment because it is simple and reproducible when performed under standardized conditions.

Established sarcopenia frameworks use low strength as an important component of assessment.

However, buying a grip-strength device and testing yourself every day is unlikely to provide much useful information.

Measurement technique matters, and hand conditions such as arthritis can affect results. The GLP-1 multisociety advisory also notes that handgrip testing may be less sensitive to some changes than other strength measures.

When grip strength is clinically relevant, standardized measurement by a trained professional is more informative than interpreting isolated home readings without context.

What about chair-rise or sit-to-stand testing?

Chair-rise performance can provide useful information about lower-body strength and function, particularly in older adults.

A clinician might assess how quickly or effectively someone can repeatedly rise from a chair under standardized conditions.

That does not mean everyone taking a GLP-1 medication needs to time themselves at home.

If you choose to monitor an everyday movement such as standing from a chair, the simplest observation may be sufficient: Has this become noticeably harder over time?

Difficulty that develops gradually and persists is more informative than obsessing over a second or two of day-to-day variation.

Who should pay particularly close attention?

Muscle monitoring becomes more important when someone starts treatment with less physiological reserve.

People who may warrant closer attention include those who are:

• older;
• frail or at risk of frailty;
• already living with low strength or low muscle mass;
• physically inactive;
• experiencing substantial appetite suppression;
• losing weight rapidly;
• recovering from illness, hospitalization, or surgery;
• living with medical conditions that can affect muscle health or nutrition.

The evidence base for GLP-1-related muscle outcomes in many of these higher-risk populations remains incomplete, which is itself a reason to avoid assuming that average clinical-trial results apply equally to everyone. Recent reviews emphasize more individualized monitoring in susceptible groups.

Older adults in particular may face different considerations because age-related muscle decline, frailty, reduced appetite, and chronic disease can overlap with medication-assisted weight loss. Our guide to GLP-1 medications and muscle loss in older adults examines those issues in greater detail.

When should you contact a healthcare professional?

Ordinary fluctuations in gym performance or energy do not necessarily require medical evaluation.

More persistent or substantial changes deserve greater attention.

Contact the clinician managing your treatment if you develop issues such as:

• persistent or progressive weakness;
• noticeably worsening mobility or ability to perform normal activities;
• repeated falls or new balance problems;
• prolonged difficulty eating enough food;
• persistent vomiting or inability to maintain hydration;
• unexpectedly rapid weight loss accompanied by poor intake or weakness;
• other concerning new symptoms.

Those problems can have many causes besides muscle loss and may require evaluation beyond body composition.

Do not stop, reduce, or increase a prescription GLP-1 medication solely because of a home muscle assessment unless your prescribing clinician has already given you specific instructions for doing so.

Do you need regular DXA scans while taking a GLP-1?

Not necessarily.

There is currently no established recommendation that every person using a GLP-1 medication should undergo routine DXA testing solely to monitor muscle.

The 2026 EASO, EFAD, and ECPO consensus statement recommends pragmatic monitoring of nutrition and physical function, with body-composition assessment where indicated, rather than universally requiring advanced testing.

Someone with low baseline muscle reserves, unexplained weakness, frailty, substantial weight loss, or another clinical concern may have more reason for formal assessment than a healthy person who remains active, adequately nourished, and strong.

The decision depends on what question the test is intended to answer.

Focus on trends, not perfect numbers

There is no single measurement that can tell you with complete certainty whether GLP-1-associated weight loss is affecting your muscles in a clinically meaningful way.

The bathroom scale is too nonspecific. Body-composition scans have limitations. Strength can fluctuate. Everyday function can be influenced by conditions unrelated to muscle.

Together, however, these measurements create a much clearer picture.

The most reassuring pattern is generally one in which body weight and fat are decreasing while strength, mobility, physical activity, nutrition, and everyday function remain reasonably stable.

A more concerning pattern is one in which substantial weight loss occurs alongside inadequate nutrition, inactivity, progressive weakness, deteriorating exercise performance, and worsening physical function.

Monitoring does not require becoming preoccupied with every pound or repetition. It simply means paying attention to the quality of the weight-loss process—not only how much weight has disappeared.

This article provides general educational information and cannot diagnose muscle loss or sarcopenia. Persistent weakness, declining mobility, inadequate nutrition, or other concerning symptoms should be assessed by an appropriate healthcare professional.

References

1. Mozaffarian D, Agarwal M, Aggarwal M, et al. “Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.” The American Journal of Clinical Nutrition, 2025.
2. Dobbie LJ, Tolvanen L, Alves D, et al. “Nutritional, Functional, and Psychological Considerations for Incretin-Based Therapies in Adults—an EASO, EFAD, and ECPO Consensus Statement.” The Lancet Diabetes & Endocrinology, 2026.
3. Menezes MLL, Chiappa MEG, Kloss RF, et al. “Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework.” Diabetes, Obesity and Metabolism, 2026.
4. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. “Sarcopenia: Revised European Consensus on Definition and Diagnosis.” Age and Ageing, 2019.
5. Alissou M, et al. “Impact of Semaglutide on Fat Mass, Lean Mass and Muscle Function in Patients With Obesity: The SEMALEAN Study.” Diabetes, Obesity and Metabolism, 2026.
6. “Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.” Nutrients, 2026.